natgillin/translations-raw huggingface dataset:
Valnemulin is well-accepted in feed, but administered at concentrations above 200 mg valnemulin / kg feed may result in transient reduction in food consumption associated with unpalatability during the first few days of feeding. 
Valnemulin je dobro prihvaćen u hrani za životinje, ali primjena u hrani za životinje u koncentracijama iznad 200 mg valnemulina/kg hrane može rezultirati u prolaznom smanjenju konzumacije hrane koje je povezano s neugodnim okusom tijekom prvih nekoliko dana hranjenja.
The required quantity of product is thoroughly mixed with a feed ingredient of similar physical nature (e.g. wheat middlings) in the proportion: 1 part Econor 10% premix to 10 parts feed ingredient. 
Potrebna količina proizvoda temeljito se miješa sa sastojkom hrane slične fizičke prirode (primjerice s finim česticama pšeničnih mekinja) u omjeru: 1 dio Econor 10 % premiksa na 10 dijelova sastojka hrane.
Do not administer the veterinary medicinal product to pigs or rabbits receiving ionophores. 
Ne primjenjivati veterinarsko-medicinski proizvod na svinjama ili kunićima koje primaju ionofore.
Treatment and prevention of swine enzootic pneumonia. 
Liječenje i prevencija enzootske pneumonije svinja.
STATEMENT OF ACTIVE SUBSTANCES Valnemulin 500 mg/g (equivalent to 532.5 mg/g valnemulin hydrochloride) 
500 mg/g (odgovara 532,5 mg/g valnemulinklorida)
10-12 mg/kg bodyweight/day 
10 - 12 mg/kg tjelesne mase/dan
Econor 10% premix for medicated feed for pigs and rabbits is available in 1 kg and 25 kg bags. 
Econor 10 % premiks za izradu ljekovite hrane za svinje i kuniće dostupan je u vrećama od 1 kg i 25
As an adjunct to medication, good management and hygiene practices should be introduced in order to reduce the risk of infection and to control the potential build-up of resistance. 
Pored veterinarsko-medicinskih proizvoda treba uvesti mjere dobre higijenske prakse kako bi se smanjio rizik od infekcije i uvela kontrola mogućeg nastanka rezistencije.
MARKETING AUTHORISATION NUMBER(S) EU/2/98/010/021 (1 kg) 
16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/98/010/021 (1 kg)
Their occurrence appears to be mainly associated with breed mixes that include Danish and/or Swedish Landrace. 
Njihovo se pojavljivanje čini uglavnom povezano s križanim pasminama koje uključuju danski i/ili švedski landras.
NAME OF THE VETERINARY MEDICINAL PRODUCT Econor 50% premix for medicated feed for pigs Econor 10% premix for medicated feed for pigs and rabbits 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Econor 50 % premiks za izradu ljekovite hrane za svinje Econor 10 % premiks za izradu ljekovite hrane za svinje i kuniće
532.5 mg/g equivalent to valnemulin 
532,5 mg/g odgovara valnemulinu
MARKETING AUTHORISATION NUMBER(S) EU/2/98/010/025 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/98/010/025
Consideration should be given to official guidance on the incorporation of medicated premixes in final feeds. 
Trebalo bi razmotriti, stavljanje ljekovitih premiksa u gotovu hranu za životinje, u službenim vodičima.
SPECIAL STORAGE PRECAUTIONS 
13. Posebne mjere čuvanja
In-feed use. 
Primjena u hrani za životinje.
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCES Valnemulin 100 mg/g (equivalent to 106.5 mg/g valnemulin hydrochloride) 
Valnemulin 100 mg/g (odgovara 106,5 mg/g valnemulinklorida)
3-4 mg/kg bodyweight/day 
3 - 4 mg/kg tjelesne mase/dan
It is important to institute treatment as early as possible in an outbreak of swine dysentery. 
Važno je organizirati liječenje bolesti čim prije u samom začetku dizenterije svinja.
Dosage guidance table 
Tablica s dnevnim vodičem doza
Name and address of the manufacturers responsible for batch release 
Naziv i adresa proizvođača odgovornog(ih) za puštanje serije u promet
Application in feed 
Primjena u hrani za životinje
Econor 50% 400 mg/kg feed Econor 10% 2 g/kg feed 
Econor 50 % 400 mg/kg hrane Econor 10 % 2 g/kg hrane
Equivalent to valnemulin base 
SASTAV DJELATNIH TVARI Valnemulin
Do not administer the product to pigs or rabbits receiving ionophores. 
Ne primjenjivati proizvod na svinjama ili kunićima koje primaju ionofore.
Incorporation of 200 mg active substance per kg feed with: 
Miješanje 200 mg djelatne tvari po kg hrane s:
Do not administer the product to pigs receiving ionophores. 
Ne primjenjivati proizvod na svinjama koje primaju ionofore.
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCES Valnemulin hydrochloride 
SASTAV DJELATNE(IH) TVARI I DRUGIH SASTOJAKA Valnemulinklorid
Treatment of clinical signs porcine proliferative enteropathy (ileitis) 
Liječenje kliničkih znakova proliferativne enteropatije svinja (ileitisa)
Special warnings for use in pigs: 
Posebna mjere opreza prilikom primjene na svinjama:
Brachyspira pilosicoli 
Epizootska enteropatija kunića
PACKAGE LEAFLET: Econor 50% premix for medicated feed for pigs 
UPUTA O VMP: Econor 50 % premiks za izradu ljekovite hrane za svinje
NAME OF THE VETERINARY MEDICINAL PRODUCT Econor 10% oral powder for pigs 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Econor 10 % peroralni prašak za svinje
PACKAGE LEAFLET: Econor 10% oral powder for pigs 
UPUTA O VMP: Econor 10 % peroralni prašak za svinje
Econor 50% 150 mg/kg feed Econor 10% 750 mg/kg feed 
Econor 50 % 150 mg/kg hrane Econor 10 % 750 mg/kg hrane
Incorporation of 75 mg active substance per kg feed with: 
Miješanje 75 mg djelatne tvari po kg hrane s:
Finisher 
kunić
Laboratory studies in rats and mice have not produced any evidence of teratogenic effect, however, the safety of the veterinary medicinal product in pregnant and lactating sows has not been established. 
Dok u laboratorijskim ispitivanjima na štakorima i miševima nisu otkriveni dokazi teratogenih učinaka, neškodljivost tijekom graviditeta i laktacije u svinja nije utvrđena.
In-feed use for rabbits: 
Primjena u hrani za kuniće:
METHOD AND ROUTE(S) OF ADMINISTRATION In-feed use. 
NAČIN I PUT(EVI) PRIMJENE
Silica Colloidal anhydrous Isopropyl myristate Lactose. 
Silicijev dioksid, koloidni, bezvodni Izopropil miristat Laktoza
Econor 50% 50 mg/kg feed Econor 10% 250 mg/kg feed 
Econor 50 % 50 mg/kg hrane Econor 10 % 250 mg/kg hrane
Econor 10% 750 mg/kg feed 
Econor 10 % 750 mg/kg hrane
NAME OF THE VETERINARY MEDICINAL PRODUCT Econor 50% premix for medicated feed for pigs Valnemulin 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Econor 50 % premiks za izradu ljekovite hrane za svinje Valnemulin
Econor 50% mg Econor 50% premix/kg feed = Dosage required (mg/kg) x 2 x bodyweight (kg)/Daily feed intake (kg). 
Econor 50 % mg Econor 50 % premiks/kg hrane = potrebna doza (mg/kg) x 2 x tjelesna masa (kg)/dnevnog unosa hrane (kg).
The treatment of clinical signs of porcine proliferative enteropathy (ileitis). 
Liječenje kliničkih znakova proliferativne enteropatije svinja (ileitisa).
NAME OF THE VETERINARY MEDICINAL PRODUCT Econor 10% oral powder for pigs Valnemulin 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Econor 10 % peroralni prašak za svinje Valnemulin
Adverse reactions following the use of Econor are mainly associated with breeds and cross- breeds of Danish and/or Swedish Landrace. 
Nuspojave nakon primjene Econora uglavnom su povezane s pasminama i mješancima danskog i/ili švedskog landrasa.
To achieve good mixture and homogeneity of incorporation, the use of a pre-mixture is recommended. 
Da biste postigli dobru smjesu i homogenost miješanja djelatne tvari preporučena je upotreba predsmjese.
WITHDRAWAL PERIOD(S) Meat and offal: 1 day. 
KARENCIJA(E) Meso i jestive iznutrice: 1 dan.
Econor 10% mg Econor 10% premix/kg feed = Dosage required (mg/kg) x 10 x bodyweight (kg)/Daily feed intake (kg). 
Econor 10 % mg Econor 10 % premiks/kg hrane = potrebna doza (mg/kg) x 10 x tjelesna masa (kg)/dnevnog unosa hrane (kg).
Marketing authorisation number(s) EU/2/98/010/017 (1 kg) EU/2/98/010/018 (25 kg) 
21. Broj(evi) odobrenja za stavljanje u promet EU/2/98/010/017 (1 kg)
Name and address of the marketing authorisation holder and of the manufacturing authorisation holder responsible for batch release, if different 
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
Incorporation of 35 mg active substance per kg feed with: 
Miješanje 35 mg djelatne tvari po kg hrane s:
1.0-1.5 mg/kg bodyweight/day minimum of 7 days and up to 4 weeks 
1,0 - 1,5 mg/kg tjelesne mase/dan
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Econor 50% premix contains valnemulin in the form of valnemulin hydrochloride. 
Econor 50 % premiks sadrži valnemulin u obliku valnemulinklorida.
Econor 10% 350 mg/kg feed 
Econor 10 % 350 mg/kg hrane
Econor 50% 400 mg/kg feed 
Econor 50 % 400 mg/kg hrane
Econor 10% 250 mg/kg feed 
Econor 10 % 250 mg/kg hrane
Swine dysentery 3-4 mg/kg bodyweight/day 
Ciljna doza 3 mg/kg tjelesne mase/dan
Mycoplasma hyopneumoniae 
Hipromeloza
Mixing instructions: mg Econor 50% premix/kg feed = Dosage required (mg/kg) x 2 x bodyweight (kg)/Daily feed intake (kg) 
Upute o miješanju: mg Econor 50 % premiks/kg hrane = potrebna doza (mg/kg) x 2 x tjelesna masa (kg)/dnevnog unosa hrane (kg)
Valnemulin hydrochloride 
Djelatna tvar valnemulinklorid
Incorporation of 25 mg active substance per kg feed with: 
Miješanje 25 mg djelatne tvari po kg hrane s:
Shelf life when incorporated into common rabbit feed and protected from light and moisture: 4 weeks. 
Rok valjanosti poslije stavljanja u standardnu hranu za kuniće i zaštićeno od svjetlosti i vlage: 4 tjedna.
Econor 50% 150 mg/kg feed 
Econor 50 % 150 mg/kg hrane
Econor 50% 50 mg/ kg feed 
Econor 50 % 50 mg/kg hrane
Shelf life when incorporated into pelleted pig feed and protected from light and moisture: 3 weeks. 
Rok valjanosti poslije stavljanja u peletiranu hranu za svinje i zaštićeno od svjetlosti i vlage: 3 tjedna.
Daily dose calculation: Amount Econor (mg) required = Dose required (mg/kg) x pig bodyweight (kg) x 10 / daily feed intake (in kg). 
Potrebna količina Econor (mg) = potrebna doza (mg/kg) x tjelesna masa svinje (kg) x 10/dnevni unos hrane (kg).
Amount Econor 10% oral powder (mg) required = Dose required (mg/kg) x pig bodyweight (kg) x 10 / daily feed intake (kg). 
Potrebna količina Econor 10 % peroralnog praška (mg) = potrebna doza (mg/kg) x tjelesna masa svinje (kg) x 10/dnevni unos hrane (kg).
Silica, colloidal anhydrous Isopropyl myristate Lactose 
Silicijev dioksid, koloidni, bezvodni Izopropilni miristat Laktoza
To achieve good mixture and homogeneity of incorporation, the use of a pre-mixture is required. 
Da biste postigli dobru smjesu i homogenost miješanja djelatne tvari potrebna je primjena predsmjese.
NAME OF THE VETERINARY MEDICINAL PRODUCT Econor 50% premix for medicated feed for pigs Valnemulin hydrochloride 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Econor 50 % premiks za izradu ljekovite hrane za svinje Valnemulinklorid
NAME OF THE VETERINARY MEDICINAL PRODUCT Econor 10% oral powder for pigs Valnemulin hydrochloride 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Econor 10 % peroralni prašak za svinje Valnemulinklorid
Grower 
NUSPOJAVE
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE ALUMINIUM-LINED PLASTIC BAGS 
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKOVANJU
Shelf life when incorporated into meal pig feed and protected from light and moisture: 3 months. 
Rok valjanosti poslije stavljanja u hranu za svinje i zaštićeno od svjetlosti i vlage: 3 mjeseca.
Sow 
kg.
The required quantity of product is thoroughly mixed with a feed ingredient of similar physical nature (e.g. wheat middlings) and for rabbits in rabbit standard feed (e.g. mash, pellets) in the proportion: 1 part Econor 10% premix to 10 parts feed ingredient. 
Potrebna količina proizvoda temeljito se miješa sa sastojkom hrane slične fizičke prirode (primjerice s finim česticama pšeničnih mekinja) te za kuniće u standardnoj hrani za kuniće
106.5 mg/g equivalent to valnemulin 100 mg/g. 
106,5 mg/g odgovara valnemulinu
mg Econor 10% premix/kg feed = Dosage required (mg/kg) x 10 x bodyweight (kg)/Daily feed intake (kg) 
Upute o miješanju: mg Econor 10 % premiks/kg hrane = potrebna doza (mg/kg) x 10 x tjelesna masa (kg)/dnevnog unosa hrane (kg)
Other provisions 
Ostali sastojci:
This dose level is effective under normal situation in the treatment of clinical signs of disease, but higher dosages or longer duration of treatment may be necessary for complete elimination of infection. 
Ta je doza djelotvorna u liječenju kliničke bolesti, ali više doze ili dulje trajanje liječenja mogu biti
Pigs 
Krmača
and Escherichia coli. 
salinomicin ili narazin.
Two hours after withdrawal of product given in feed twice daily for 4 weeks at a dose of 15 mg/kg bodyweight/day, liver concentration was 1.58 µg/g and lung concentration 0.23 µg/g whereas concentrations in plasma were below the limit of detection. 
Dva sata nakon povlačenja premiksa koji se primjenjuje u hrani za životinje dva puta dnevno tijekom četiri tjedna pri dozi od 15 mg/kg tjelesne mase/dan,
Pharmacologically active substance 
Farmakološk i djelatna tvar
* colony forming units 
* jedinice koje stvaraju kolonije
1.3∙108 to 9.0∙108 CFU*/dose. 
-1 Živa nepatogena Escherichia coli O8:K87: 1.3∙108 do 9.0∙108 CFU*/dozi.
Vial (glass) 50 doses 4 vials Zero days 
50 doza 4 bočice Nula dana
Can't be sold separately. 
Ne može se prodavati zasebno.
Date of latest renewal: 28 April 2017. 
Datum posljednje obnove odobrenja: 28. travanj 2017.
The response rate in these patients was about 52 %. 
Stopa odgovora u ovih bolesnika bila je približno 52%.
Currently available data are described in section 5.1 but no recommendation on a posology can be made. 
Trenutno dostupni podaci opisani su u dijelu 5.1 međutim, nije moguće dati preporuku o doziranju.
The occurrence of osteonecrosis is multifactorial and is associated with various risk factors. 
Pojavljivanje osteonekroze je multifaktorijalno i povezano je s različitim faktorima rizika.
Many of these patients were also receiving chemotherapy and corticosteroids and had signs of local infection including osteomyelitis. 
Mnogi od tih bolesnika također su primali kemoterapiju i kortikosteroide i imali su znakove lokalne infekcije uključujući osteomijelitis.
Anxiety, sleep disturbance Confusion 
anksioznost, poremećaj spavanja konfuzija
If any of these apply to you, tell your doctor straight away. 
Ako se nešto od navedenog odnosi na Vas, odmah obavijestite liječnika.
- A kidney function disorder called Fanconi syndrome (will normally be determined by your doctor with certain urine tests). 
- Poremećaj rada bubrega koji se zove Fanconijev sindrom (obično ga utvrđuje Vaš liječnik pomoću određenih testova urina).
- Severe allergic reaction: shortness of breath, swelling mainly of the face and throat. 
- teška alergijska reakcija: nedostatak zraka, oteklina koja uglavnom zahvaća lice i grlo.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 03 August 2012. 
Datum prvog odobrenja: 3. kolovoza 2012.
In some instances the hypocalcaemia may be life-threatening. 
U nekim situacijama hipokalcemija može biti životno opasna.
In some instances, the hypocalcaemia may be life-threatening (see section 4.8). 
U nekim situacijama hipokalcemija može biti životno opasna (vidjeti dio 4.8).
• Potency of the bisphosphonate (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bisphosphonate. 
• jakost bisfosfonata (veći rizik za vrlo jake spojeve), put primjene (veći rizik pri parenteralnoj primjeni) i kumulativna doza bisfosfonata.
The contributive role of zoledronic acid therapy in these cases could not be excluded. 
Doprinos terapije zoledronatnom kiselinom u ovim slučajevima se ne može isključiti.
- Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. 
Obratite se liječniku ako imate bol u uhu, iscjedak iz uha i/ili infekciju uha.
The time to onset for occurrence of osteonecrosis also has similar pattern when compared to osteonecrosis of the jaw/external auditory canal. 
Vrijeme do pojave osteonekroze također ima sličan obrazac kad se uspoređuje s osteonekrozom čeljusti/vanjskog slušnog kanala.
• The total time between dilution, storage in the refrigerator and end of administration must not exceed 96 hours. 
• Ukupno vrijeme od razrjeđenja i čuvanja u hladnjaku do završetka primjene ne smije biti dulje od 96 sati.
If a lower dose of Zoledronic acid medac is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution. 
Ako je potrebna niža doza Zoledronatne kiseline medac, prvo izvucite odgovarajući volumen kako je navedeno niže, i potom ga dodatno razrijedite sa 100 ml otopine za infuziju.
- Painful redness and/or swelling of the eye. 
- bolno crvenilo i/ili oticanje oka.
Your doctor, pharmacist or nurse knows how to store Zoledronic acid medac properly (see section 6). 
Vaš liječnik, ljekarnik ili medicinska sestra znaju kako ispravno čuvati Zoledronatnu kiselinu medac (vidjeti dio 6).
Unopened bottle: 3 years. 
6.3 Rok valjanosti Neotvorena boca: 3 godine.
Zoledronic acid medac is not recommended for use in adolescents and children below the age of 18 years. 
Ne preporučuje se primjena Zoledronatne kiseline medac u adolescenata i djece mlađe od 18 godina.
• Concomitant therapies: chemotherapy, angiogenesis inhibitors (see section 4.5), radiotherapy to neck and head, corticosteroids. 
• istodobnu terapiju: kemoterapiju, inhibitore angiogeneze (vidjeti dio 4.5), radioterapiju glave i vrata, kortikosteroide.
Therefore, the product information should be updated to reflect in sections 4.4 and 4.8 of the SmPC a warning on osteonecrosis of other anatomical sites and add this adverse reaction with a frequency very rare. 
Zbog toga je potrebno ažurirati informacije o lijeku da SmPC u dijelovima 4.4 i 4.8 sadrži upozorenje o osteonekrozi na drugim anatomskim mjestima te da se doda ova nuspojavu s učestalošću vrlo rijetko.
- to reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour. 
- smanjenje količine kalcija u krvi u odraslih bolesnika kad je količina kalcija prevelika zbog prisutnosti tumora.
- Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite. 
- reakcije probavnog sustava, kao što su mučnina i povraćanje, kao i gubitak apetita
Pyrexia, fatigue Acute phase reaction, pain 
pireksija, umor reakcija akutne faze, bol
After dilution of the concentrate the prepared solution should be clear, colourless and free of visible particles. 
Nakon razrjeđenja koncentrata pripremljena otopina treba biti bistra, bezbojna i bez vidljivih čestica.
• The total time between dilution, storage in the refrigerator and end of administration must not exceed 24 hours. 
• Ukupno vrijeme od razrjeđenja i čuvanja u hladnjaku do završetka primjene ne smije biti dulje od 24 sata.
The analysis of the individual safety reports from clinical trials, spontaneous reports and literature retrieved 62 cases of osteonecrosis of other anatomical sites in association with zoledronic acid, with the majority of events occurring in the hip/femur (46). 
Analizom pojedinačnih izvješća o sigurnosti iz kliničkih ispitivanja, spontanih prijava i literature dobivena su 62 slučaja osteonekroze na drugim anatomskim mjestima povezana sa zoledronatnom kiselinom, gdje se većina događaja pojavila na kuku/bedrenoj kosti (46).
- Low level of red blood cells (anaemia). 
- konjunktivitis - smanjeni broj crvenih krvnih stanica (anemija).
Additional information on handling of Zoledronic acid medac, including guidance on preparation of reduced doses, is provided in section 4.2. 
Dodatne informacije o rukovanju Zoledronatnom kiselinom medac, uključujući upute za pripremu sniženih doza, nalaze se u dijelu 4.2.
There are no site specific risk factors for osteonecrosis apart from additional oral risk factors for osteonecrosis of the jaw. 
Nema faktora rizika za osteonekrozu koji su specifični za neko mjesto osim dodatnog oralnog faktora rizika za osteonekrozu čeljusti.
Hypersensitivity reaction Angioneurotic oedema 
reakcija preosjetljivosti angioneurotski edem
If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of Zoledronic acid medac. 
Ako već imate hipokalcemiju, ona se mora korigirati prije uvođenja prve doze Zoledronatne kiseline medac.
- Osteonecrosis has also very rarely been seen occurring with other bones than the jaw, especially the hip or thigh. 
- Uočeno je da se osteonekroza također vrlo rijetko pojavila i na drugim kostima osim čeljusti, naročito na kuku ili bedrima.
• Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking. 
• rak, komorbidna stanja (npr. anemija, koagulopatije, infekcija), pušenje.
In use stability: Chemical and physical in-use stability after dilution has been demonstrated for 24 hours at 2-8°C and 25°C. 
Stabilnost u primjeni: dokazana kemijska i fizikalna stabilnost nakon razrjeđivanja iznosi 24 sata na temperaturi od 2 - 8°C i 25°C.
- Low level of calcium in the blood. 
- niska razina fosfata u krvi.
Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of a condition called osteonecrosis of the jaw. 
Odmah se obratite svom liječniku i zubaru ako imate bilo kakav problem u ustima ili sa zubima, kao što je klimanje zuba, bol ili oticanje, ranice koje ne zacjeljuju ili iscjedak, jer to mogu biti znakovi stanja koje se zove osteonekroza čeljusti.
After first opening and dilution: From a microbiological point of view the medicinal product should be used immediately. 
Nakon prvog otvaranja i razrjeđenja: s mikrobiološkog stanovišta, lijek treba odmah primijeniti.
• History of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures (e.g. tooth extractions) and poorly fitting dentures. 
• stomatološka povijest bolesti, lošu oralnu higijenu, periodontalnu bolest, invazivne zahvate na zubima (npr. vađenje zuba) i zubne proteze koje loše prijanjaju.
- Low blood pressure. 
- nesvjestica zbog niskog krvnog tlaka
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of zoledronic acid along with driving and operating of machinery. 
Nuspojave poput omaglice i somnolencije mogu utjecati na sposobnost upravljanja vozilima i rada sa strojevima te je stoga potreban oprez kad se tijekom primanja zoledronatne kiseline upravlja vozilima i radi sa strojevima.
Increasing the infusion time from 5 to 15 minutes caused a 30 % decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve. 
Produljenje trajanja infuzije s 5 na 15 minuta prouzročilo je 30%-tno sniženje koncentracije zoledronatne kiseline na kraju infuzije, ali nije imalo nikakvog učinka na površinu ispod krivulje koncentracije u plazmi u vremenu mjerenja.
Healthcare professionals are advised not to dispose of unused Zoledronic acid medac via the domestic sewage system. 
Zdravstvenim radnicima se savjetuje da ne bacaju neiskorištenu Zoledronatnu kiselinu medac u otpadne vode.
The reports of osteonecrosis at other sites with zoledronic acid suggest similarity in reporting frequency (femur>knee>humerus) as compared to the commonly affected sites of osteonecrosis based on anatomical factors. 
Prijave osteonekroze na drugim mjestima sa zoledronatnom kiselinom ukazuju na sličnu učestalost u prijavljivanju (bedrena kost>koljeno>nadlaktična kost) u odnosu na uobičajeno zahvaćena mjesta osteonekrozom temeljena na anatomskom značajkama.
Hypocalcaemia is an important identified risk with zoledronic acid in the approved indications. 
Hipokalcemija je važan prepoznat rizik primjene zoledronatne kiseline u odobrenim indikacijama.
The plasma protein binding is low, with the unbound fraction ranging from 60% at 2 ng/ml to 77% at 2,000 ng/ml of zoledronic acid. 
Vezanje za proteine plazme je nisko, s nevezanom frakcijom u rasponu od 60% kod 2 ng/ml do 77% kod 2000 ng/ml zoledronatne kiseline.